Trial · NCT03660475
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Ocular Surface Disease Index | Naltrexone | 21.17 | Standard Deviation 17.72 | score on a scale | |
| Total Ocular Surface Disease Index | Placebo | 21.36 | Standard Deviation 17.16 | score on a scale | |
| Lissamine Green Staining | Naltrexone | 2.65 | Standard Deviation 1.10 | score on a scale | |
| Lissamine Green Staining | Placebo | 2.59 | Standard Deviation 1.25 | score on a scale | |
| Tear Film Break-up Time | Naltrexone | 2.76 | Standard Deviation 0.98 | seconds | |
| Tear Film Break-up Time | Placebo | 3.48 | Standard Deviation 2.49 | seconds | |
| Conjunctival Redness | Naltrexone | 1.0 | Standard Deviation 0.41 | score on a scale | |
| Conjunctival Redness | Placebo | 1.0 | Standard Deviation 0.45 | score on a scale | |
| Schirmer's Test | Naltrexone | 8.97 | Standard Deviation 8.00 | mm | |
| Schirmer's Test | Placebo | 12.48 | Standard Deviation 9.20 | mm | |
| Cochet-Bonnet Corneal Sensitivity Test | Naltrexone | 59.78 | Standard Deviation 0.95 | cm | |
| Cochet-Bonnet Corneal Sensitivity Test | Placebo | 59.37 | Standard Deviation 1.44 | cm | |
| Tear Osmolarity | Naltrexone | 304.31 | Standard Deviation 14.11 | mOsm/L | |
| Tear Osmolarity | Placebo | 310.66 | Standard Deviation 12.16 | mOsm/L | |
| Matrix Metalloprotienase-9 (MMP-9) is a Marker of Inflammation. | Naltrexone | 3 | Participants | ||
| Matrix Metalloprotienase-9 (MMP-9) is a Marker of Inflammation. | Placebo | 3 | Participants | ||
| Ocular Discomfort (Scale 1) | Naltrexone | 1.03 | Standard Deviation 1.10 | score on a scale | |
| Ocular Discomfort (Scale 1) | Placebo | 1.07 | Standard Deviation 1.13 | score on a scale | |
| Ocular Discomfort (Scale 2) | Naltrexone | 1.40 | Standard Deviation 1.25 | score on a scale | |
| Ocular Discomfort (Scale 2) | Placebo | 1.45 | Standard Deviation 1.57 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03660475/results